Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015839
Chunk: 91

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 91
---
     |                                $ |   |     |          $ |   |     |     Change |   |
| Cash used in operating activities     |     |                       (9,409,825 | ) |     | (3,953,639 | ) |     | (5,456,186 | ) |
| Cash provided by financing activities |     |                       14,915,048 |   |     | 10,642,500 |   |     |  4,272,548 |   |
| Net change in cash during the period  |     |                        5,505,223 |   |     |  6,688,861 |   |     | (1,183,638 | ) |
| Cash, beginning of the period         |     |                        4,164,323 |   |     |  1,719,338 |   |     |  2,444,985 |   |
| Cash, end of the period               |     |                        9,669,546 |   |     |  8,408,199 |   |     |  1,261,347 |   |

Cash flows used in operating activities

Cash flows used in operating activities for the six months ended June 30, 2025 were $9,409,825 compared to cash flows used in operating activities of $3,953,639 for the six months ended June 30, 2024. The increase is primarily due to increased spending on research and development activities for our SKNJCT-003 study and trials and increased general and administrative expenses related to our IPO and resulting U.S. reporting obligations, along with multiple financing and other transactional activities.

Cash flows provided by financing activities

Cash flows provided by financing activities for the six months ended June 30, 2025 were $14,915,048 due to $9,790,015 of proceeds from issuance of common shares and warrants, net of offering costs, gross proceeds of $4,500,000 from the issuance of the Debentures, as well as proceeds of $977,398 from the exercises of warrants. Cash flows provided by financing activities for the six months ended June 30, 2024 were $10,642,500 consisting of $5,172,500 of proceeds from issuance of convertible notes and $5,470,000 of proceeds from issuance of common shares and warrants.

|                                       |     | For the year ended December 31,